HGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 25, 2022 in the Class Action Filed on Behalf of Humanigen, Inc. Shareholders

NEW YORK, Oct. 25, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Humanigen, Inc. (NASDAQ: HGEN) alleging that the Company violated federal securities laws.

Class Period: May 16, 2020 to July 12, 2022
Lead Plaintiff Deadline: October 25, 2022
No obligation or cost to you.

Learn more about your recoverable losses in HGEN:
https://www.kleinstocklaw.com/pslra-1/humanigen-inc-class-action-loss-submission-form?id=32934&from=4

Humanigen, Inc. NEWS - HGEN NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that Humanigen, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Humanigen's lead product candidate, lenzilumab, posed risks to patients in addition to those disclosed by defendants; (ii) lenzilumab was not the only immunomodulator currently in late-stage clinical trials; (iii) lenzilumab was less effective in treating hospitalized COVID-19 patients than defendants had represented; (iv) as a result, the U.S. Food and Drug Administration was unlikely to approve the lenzilumab Emergency Use Authorization and the ACTIV-5/BET-B study was unlikely to meet its primary endpoint; (v) accordingly, lenzilumab's clinical and commercial prospects were overstated; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Humanigen you have until October 25, 2022 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased Humanigen securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the HGEN lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link: https://www.kleinstocklaw.com/pslra-1/humanigen-inc-class-action-loss-submission-form?id=32934&from=4.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
535 Fifth Avenue
4th Floor
New York City, NY 10017
[email protected]
Telephone: (212) 616-4899
www.kleinstocklaw.com

SOURCE The Klein Law Firm